Clinical Trial Update: Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TRC105 in recurrent ovarian, fallopian tube, or primary peritoneal carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• TRC105 (carotuximab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Recurrent Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-03-05